Despite evidence illustrating medications for treating opioid use disorder (MOUD)—namely buprenorphine, methadone, and extended-release naltrexone—are effective at treating the disorder and reducing associated harms, there remains a distinct underutilization of MOUD. This lack of usage stems largely from an under-supply of trained providers, particularly those willing to prescribe MOUD.

This study looks to understand comparative beliefs about MOUD and barriers to usage of MOUD with a mixed-methods approach involving focus group interviews and an online physician survey. Focus group results were thematically analyzed, with survey results using descriptive and inferential statistical methods.

This publication was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $900,000. The contents are those of the author and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.